Quick, Reliable Marker to PUSH Decongestive Therapy in AHF

Recorded August 28, 2023. This transcript has been edited for clarity.

Ileana L. Piña, MD, MPH: Hello! I'm Ileana Piña, professor of medicine at Thomas Jefferson University, and a heart failure transplant cardiologist. I am here at the European Society of Cardiology.

There's been a large amount of talk at this meeting about diuretics — those wonderful drugs that none of us really know how to give, how to use, how to recommend — and when anybody wants the standard of care, it depends upon what hospital you're in and what city you're in. We need to decongest patients. There's no doubt about it.

Now, with the sodium-glucose cotransporter 2 (SGLT2) data, there are still discussions about whether that's a diuretic and what to do with the loop diuretics when you put the patient on the SGLT2? It doesn't matter whether it's empagliflozin or dapagliflozin; it's basically the same.

This is a very interesting trial that we're going to talk about, and I have my good friend here, Wilfried Mullens from Belgium, who will be a discussant in this trial. The trial was called PUSH-AHF. Tell me about this PUSH concept of natriuresis.

PUSH-AHF

Wilfried Mullens, MD, PhD:The trial was designed based on a